CEL-SCI presents new data for its LEAPS vaccine in the treatment of RA
CEL-SCI Corporation announced that Daniel Zimmerman, Ph.D., its SVP of Research, Cellular Immunology, presented new LEAPS data at the American Association of Immunologists 103th Annual Meeting in San Diego, California on Saturday, May 11, 2019. The title of his presentation is "Therapeutic vaccination by two DerG LEAPS conjugates incorporating different PG epitopes protect by different immune mechanisms in the PG G1 domain induced mouse model of rheumatoid arthritis". The work was performed in conjunction with researchers at Rush University Medical Center, Chicago, Illinois. CEL-4000 and a newly discovered LEAPS conjugate, DerG-PG275Cit, were evaluated alone and in combination in the sister model of proteoglycan induced arthritis called recombinant PG G1 domain-induced arthritis, an autoimmune mouse model of rheumatoid arthritis. The LEAPS platform technology is currently being utilized to develop a therapeutic antigen-specific treatment for RA under a $1.5M grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases, part of the National Institutes of Health. Upon completion of preclinical and Investigational New Drug enabling studies for the antigen-specific LEAPS vaccine treatment of RA, CEL-SCI intends to file an IND application with the U.S. Food and Drug Administration.